Experimental reactivation of latent canine herpesvirus-1 and induction of recurrent ocular disease in adult dogs.
Latent canine herpesvirus-1 (CHV-1) infection is common in domestic dogs, but recrudescent CHV-1 diseases are poorly characterized. To determine if administration of an immunosuppressive dosage of prednisolone to adult dogs latently infected with CHV-1 results in recurrent ocular disease, adult beagles with and without experimentally induced CHV-1 latent infection were divided into groups: group 1 latently infected and administered prednisolone, group 2 latently infected and administered placebo, and group 3 not latently infected and administered prednisolone. Prednisolone (3.0 mg/kg/day) was administered to dogs in groups 1 and 3 for seven consecutive days beginning on study day 1. Samples for CHV-1 polymerase chain reaction and serum neutralization (SN) assays were collected, and physical, ophthalmologic, and in vivo ocular confocal microscopic examinations were performed at intervals for 42 days. Bilateral ocular disease (i.e., conjunctivitis or keratitis) was detected in 83% of group 1 dogs between study days 3 and 18. In vivo confocal microscopic abnormalities included conjunctival leukocyte infiltration and corneal leukocyte infiltration, abnormal epithelial cell morphology, and Langerhans cell infiltration. Ocular viral shedding was detected in 50% of group 1 dogs on study days 10 and 13. Fourfold elevations in CHV-1 SN titers were detected in 100% of group 1 dogs by study day 14. Dogs in control groups did not develop clinical ocular disease (P<0.05), CHV-1 titer elevations (P<0.005), or viral shedding. Administration of an immunosuppressive dosage of systemic prednisolone to adult dogs latently infected with CHV-1 may result in viral reactivation and ocular disease recrudescence.
Ledbetter
Eric C
EC
Cornell University, College of Veterinary Medicine, Department of Clinical Sciences, Ithaca, NY 14853, United States. ecl32@cornell.edu
Kim
Sung G
SG
Dubovi
Edward J
EJ
Bicalho
Rodrigo C
RC
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D017931:DNA Primers; D004283:Dog Diseases / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology / Q000821:virology*; D004285:Dogs; D005123:Eye / Q000821:virology; D005128:Eye Diseases / Q000503:physiopathology / Q000662:veterinary*; D005260:Female; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000235:genetics; D006566:Herpesviridae Infections / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000662:veterinary*; D002184:Herpesvirus 1, Canid / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology*; D007165:Immunosuppression Therapy; D008297:Male; D009500:Neutralization Tests; D010919:Placebos; D011239:Prednisolone / Q000627:therapeutic use*; D013937:Thymidine Kinase / Q000235:genetics; D019562:Viral Load; D014775:Virus Activation; D017201:Virus Shedding
D000893:Anti-Inflammatory Agents; D017931:DNA Primers; D010919:Placebos; D011239:Prednisolone; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases; D013937:Thymidine Kinase